Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2014. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of September 30, 2014:
- Total Issued Ordinary Shares: 5,351,907,247 (25p each)
- Treasury Shares: 502,139,179
- Total Voting Rights: 4,849,768,068
No comparative data for prior periods is included in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,849,768,068) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (502,139,179) to calculate the correct denominator for ownership percentage calculations.
- Review the Company's Form 20-F for comprehensive financial performance data, as this 6-K does not contain financial results.